Author/Authors :
Jonsson، نويسنده , , Elin and Friberg، نويسنده , , Lena E and Karlsson، نويسنده , , Mats O and Hassan، نويسنده , , Saadia B and Nygren، نويسنده , , Peter and Kristensen، نويسنده , , Jِrgen and Tholander، نويسنده , , Bengt and Binderup، نويسنده , , Lise and Larsson، نويسنده , , Rolf، نويسنده ,
Abstract :
Fresh human tumour cells from patients with ovarian cancer and chronic lymphocytic leukaemia were cultured in semipermeable hollow fibres. The fibres were implanted on immunocompetent rats, which were treated with the cyanoguanidine N-(4-chlorophenoxyhexyl)-N′-cyano-N″-4-pyridylguanidine (CHS 828). CHS 828 showed high antitumour activity against all eight tumour samples; the fibres from control animals had a mean net growth of 73% while CHS 828 treatment induced a 37% mean reduction of cell density, without observable haematological toxicity. The results show a feasibility of using tumour cells directly from patients in the hollow-fibre rat model.
Keywords :
Hollow fibre , Cyanoguanidine , drug development , Anticancer drug , Primary human tumour cell
